Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

_					
Mar	nuscript title: Kræft i	urinblæren			
Manuscript number (if known):					
are i third com	related to the content of your parties whose interests n	our manuscr nay be affect and does no	ript. "Related" ted by the cor t necessarily i	' means any relatio ntent of the manus ndicate a bias. If yo	vities/interests listed below that n with for-profit or not-for-profit cript. Disclosure represents a ou are in doubt about whether to
	following questions apply nuscript only.	to the autho	or's relationsh	ips/activities/intere	ests as they relate to the <u>current</u>
pert		of hypertens	ion, you shou	ld declare all relation	or example, if your manuscript onships with manufacturers of he manuscript.
	em #1 below, report all super items, the time frame fo				ot without time limit. For all
		none (add r needed)	have this o or indicate rows as	Specifications/Con (e.g., if payments v institution)	nments were made to you or to your
Time	e frame: Since the initial plar	nning of the w	vork		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	x□ None			
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	x□ None			
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	x□ None			Click TAB in last row to add extra rows
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	x□ None			Click TAB in last row to add extra rows
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	iny entity	□ None		Click TAB in last row to add extra rows Grants from Pfizer and Merck for bladder cancer research within the last 5 years.
Time	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from a	iny entity above).	□ None x□ None		Grants from Pfizer and Merck for bladder cancer research

Date: 05022023

4	Consulting fees	x□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x□ None	
6	Payment for expert testimony	x□ None	
7	Support for attending meetings and/or travel	x□ None	
8	Patents planned, issued or pending	x□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	Head of VMK komité 1
11	Stock or stock options	x□ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x□ None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other		

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.	

Dot	01 2 felomor 2022		
Dat			
	Ir name: Dag Rune Storm	noen	
Ma	nuscript title: Kræft i	urinblæren	
Ma	nuscript number (if known):	
are r third comi list a The f	elated to the content of yo parties whose interests ma mitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	ains to the epidemiology of hypertensive medication, ev	hypertension, you should yen if that medication is no port for the work reporter	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months
		, , , , , , , , , , , , , , , , , , , ,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
	e frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work None	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work None None None Merck EMD Pfizer	Specifications/Comments (e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows Research grant to Rigshospitalet
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work None None	Specifications/Comments (e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows Research grant to Rigshospitalet

4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None MSD	Payment made to institution (Rigshospitalet)
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	□ None Merck	ESMO 2022.
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	None Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non	
13	Other financial or non- financial interests	None Non	

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date:	05022023			
Your	name: Pernille Skjold K	ingo		
Manuscript title: Kræft i urinblæren				
Manu	uscript number (if known)):		
are re third comm list a r	elated to the content of your parties whose interests mitment to transparency a relationship/activity/inter	our manuscrip hay be affecte and does not i est, it is prefe	ot. "Related" ed by the con necessarily in erable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a ndicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
	uscript only.	to the author	3 1610113111	ps/activities/interests as they relate to the <u>current</u>
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all enti whom you ha relationship o none (add ro needed)	ave this or indicate ws as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	frame: Since the initial plan		ork	
	All support for the present manuscript (e.g., funding,	x□ None		
p	provision of study			
	materials, medical writing, article processing charges,			
€	etc.)			
r	No time limit for this			
i	item.			
				Click TAB in last row to add extra row
Time	frame: past 36 months			
2	Grants or contracts from a (if not indicated in item #1	3	□ None	
3	Royalties or licenses	Х	□ None	

4	Consulting fees	x□ None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Educational course in TURB	Olympus	
6	Payment for expert testimony	x□ None		
7	Support for attending meetings and/or travel	x□ None		
8	Patents planned, issued or pending	x□ None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	x□ None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x□ None		
11	Stock or stock options	x□ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x□ None		
13	Other financial or non-financial interests	x□ None		

Please place an "X" next to the following statement to indicate your agreement:

 $X \square X$ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Ilst a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Date	: 05022023				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., unding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months	Your name: Ulla Nordström Joensen					
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed.) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra row. Click TAB in last row to add extra row.	Man	Manuscript title: Kræft i urinblæren				
are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Mail support for the present manuscript (e.g., if payments were made to you or to your institution) All support for the present manuscript (e.g., final payments were made to you or to your institution) All support for the present manuscript (e.g., final payments were made to you or to your institution) All support for the present manuscript (e.g., final payments were made to you or to your institution) All support for the present manuscript (e.g., final payments were made to you or to your institution) All support for the present manuscript (e.g., final payments were made to you or to your institution) Click TAB in last row to add extra rows Time frame: past 36 months Time frame: past	Manı	uscript number (if known)):			
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to					
pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work x None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months X None			to the auth	nor's relationsh	ips/activities/inter	ests as they relate to the <u>current</u>
other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	perta antih	ains to the epidemiology on sypertensive medication, e	f hyperter even if that	sion, you shoul medication is I	ld declare all relation not mentioned in t	onships with manufacturers of he manuscript.
whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months						ot without time innit. For all
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months			whom you relationsh none (add needed)	u have this ip or indicate I rows as	(e.g., if payments v	
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months						
provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months			x⊔ None	9		
article processing charges, etc.) No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months 2 Grants or contracts from any entity X□ None		provision of study				
No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months 2 Grants or contracts from any entity X None		o de la companya de				
No time limit for this item. Click TAB in last row to add extra rows Time frame: past 36 months 2 Grants or contracts from any entity X None						
item. Click TAB in last row to add extra rows Time frame: past 36 months 2 Grants or contracts from any entity X□ None		,				
Click TAB in last row to add extra rows Time frame: past 36 months 2 Grants or contracts from any entity X None						
Time frame: past 36 months 2 Grants or contracts from any entity X None		item.				
2 Grants or contracts from any entity X□ None					(Click IAB in last row to add extra rows
	Time	frame: past 36 months				
	2	Grants or contracts from a	nv entitv	X□ None		
				N= IIIII		
3 Royalties or licenses x□ None	3	Royalties or licenses		x□ None		

4	Consulting fees	x□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x□ None	
6	Payment for expert testimony	x□ None	
7	Support for attending meetings and/or travel	x□ None	
8	Patents planned, issued or pending	x□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	x□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	Member Medicinrådet
11	Stock or stock options	x□ None	
11 12	Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	x□ None x□ None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other		

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	0 : 5. februar 2023		
	r name: Andreas Carus		
		urinblæren	
	nuscript number (if known		
IVIGI	Tascript Harriber (II Known	<i>)</i> ·	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all sup titems, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar	-	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
		<u> </u>	Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None Non	
3	Noyumes of moonses	RA MOLIC	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal